Arylalkylamine Pharmaceutical Composition Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions containing arylalkylamine compounds, such as (4-{(3S)-3-[(1R)-1-(naphthalen-1-yl)ethylamino]pyrrolidin-1-yl}phenyl)acetic acid, lack stability against light and heat, and there is a need for a stable formulation suitable for use as a pharmaceutical product to treat hyperparathyroidism.
Innovation Solution
A pharmaceutical composition comprising (4-{(3S)-3-[(1R)-1-(naphthalen-1-yl)ethylamino]pyrrolidin-1-yl}phenyl)acetic acid or its pharmacologically acceptable salt, combined with diluents like lactose, mannitol, and cellulose, along with additives like hydroxypropylcellulose, calcium carbonate, and a coating film to enhance stability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If Compound A is used as a pharmaceutical composition without additional stabilizing agents, then the composition is simple and easy to manufacture, but the stability against light and heat is insufficient
Solution Approach 1:
The patent combines Compound A with multiple excipients including mannitol, crystalline cellulose, and coating agents to create a composite pharmaceutical composition. This composite structure provides enhanced stability against light and heat while maintaining manufacturability through standard pharmaceutical processing techniques.
Solution Approach 2:
The patent applies a coating film containing inorganic substances and coloring agents to the pharmaceutical composition. This thin film structure protects Compound A from light exposure and environmental factors, significantly improving photostability and overall composition stability.
2Stability of the object's composition
If a coating film with inorganic substances is applied to improve photostability, then stability against light is improved, but the device complexity and manufacturing process become more complex
Solution Approach 1:
The patent optimizes the coating parameters including the composition ratios of inorganic substances, coloring agents, and coating polymers. By carefully controlling these parameters, the coating process achieves effective photoprotection while remaining compatible with standard pharmaceutical manufacturing capabilities.
3Stability of the object's composition
If multiple excipients and additives are included to improve stability, then the stability and bioavailability are enhanced, but the composition complexity increases
Solution Approach 1:
The patent selects excipients that serve multiple functions: mannitol provides stability and acts as a diluent, crystalline cellulose enhances structural integrity and stability, and the coating film simultaneously provides photoprotection and controlled release properties. This multi-functionality reduces the need for additional separate components.
Data Source
AI summary
The present invention provides a pharmaceutical composition and the like comprising (4-{(3S)-3-[(1R)-1-(naphthalen-1-yl)ethylamino]pyrrolidin-1-yl}phenyl)acetic acid (Compound A) or a pharmacologically acceptable salt thereof and a diluent.